AUTHOR=Wang Hai , Zhang Xin , Liu Jiahui , Chen Wenlin , Guo Xiaopeng , Wang Yaning , Wang Yuekun , Xing Hao , Liang Tingyu , Shi Yixin , Liu Delin , Yang Tianrui , Xia Yu , Li Junlin , Wu Jiaming , Liu Qianshu , Qu Tian , Guo Siying , Li Huanzhang , Zhang Kun , Li Yilin , Jin Shanmu , Zhao Dachun , Wang Yu , Ma Wenbin 

TITLE=Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors

JOURNAL=Frontiers in Neuroscience

VOLUME=18

YEAR=2024

URL=https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1308627

DOI=10.3389/fnins.2024.1308627

ISSN=1662-453X

ABSTRACT=<sec id="sec1"><title>Background</title><p>The 2021 World Health Organization Classification of Central Nervous System Tumors updates glioma subtyping and grading system, and incorporates <italic>EGFR</italic> amplification (Amp) as one of diagnostic markers for glioblastoma (GBM).</p></sec><sec id="sec2"><title>Purpose</title><p>This study aimed to describe the frequency, clinical value and molecular correlation of <italic>EGFR</italic> Amp in diffuse gliomas based on the latest classification.</p></sec><sec id="sec3"><title>Methods</title><p>We reviewed glioma patients between 2011 and 2022 at our hospital, and included 187 adult glioma patients with available tumor tissue for detection of <italic>EGFR</italic> Amp and other 59 molecular markers of interest. Clinical, radiological and pathological data was analyzed based on the status of <italic>EGFR</italic> Amp in different glioma subtypes.</p></sec><sec id="sec4"><title>Results</title><p>163 gliomas were classified as adult-type diffuse gliomas, and the number of astrocytoma, oligodendroglioma and GBM was 41, 46, and 76. <italic>EGFR</italic> Amp was more common in IDH-wildtype diffuse gliomas (66.0%) and GBM (85.5%) than IDH-mutant diffuse gliomas (32.2%) and its subtypes (astrocytoma, 29.3%; oligodendroglioma, 34.8%). <italic>EGFR</italic> Amp did not stratify overall survival (OS) in IDH-mutant diffuse gliomas and astrocytoma, while was significantly associated with poorer OS in IDH-wildtype diffuse gliomas, histologic grade 2 and 3 IDH-wildtype diffuse astrocytic gliomas and GBM.</p></sec><sec id="sec5"><title>Conclusion</title><p>Our study validated <italic>EGFR</italic> Amp as a diagnostic marker for GBM and still a useful predictor for shortened OS in this group.</p></sec>